13F Holdings
中文EN

RNTX Rein Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1420565 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY15.6%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-100.5%
ROA-87.9%
ROIC (approx.)-85.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets11.2%
Debt / equity0.00x
Current ratio6.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.45x
Accruals ratio-48.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$0$0$0
R&D expense$11.03M$14.25M$3.99M$17.97M$17.01M
SG&A expense$10.90M$13.86M$11.36M$9.68M$9.60M
Operating income-$50.63M-$65.11M-$16.28M-$27.65M-$26.61M
Income tax-$712,000-$1.54M$0$0$0
Net income-$49.87M-$62.88M-$15.73M-$27.33M-$26.16M
EBITDA-$50.63M-$65.05M-$16.16M-$27.48M-$26.48M
EPS (basic)-1.96-3.51-3.42-6.02-5.89
EPS (diluted)-1.96-3.51-3.42-6.02-5.89
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)25.44M17.94M4.60M4.54M4.44M
Balance sheet
Cash & equivalents$3.21M$12.87M$17.34M$5.19M$3.60M
Short-term investments$0——$16.05M$42.33M
Current assets$4.33M$13.66M$18.27M$21.87M$48.18M
PP&E, net$0$1,000$19,000$70,000$128,000
Goodwill$6.33M$6.33M$6.33M——
Intangibles$13.50M$42.20M$79.20M——
Total assets$24.16M$62.19M$106.01M$22.01M$48.48M
Current liabilities$6.18M$5.75M$4.38M$3.38M$4.51M
Total liabilities$7.24M$7.80M$7.71M$3.38M$4.58M
Shareholders' equity$16.92M$54.39M$98.30M$18.62M$43.90M
Shares outstanding27.55M21.67M4.89M4.54M4.53M
Cash flow statement
Operating cash flow-$19.36M-$22.29M-$19.81M-$24.86M-$23.75M
Capital expenditure————$157,000
Free cash flow————-$23.91M
Investing cash flow—$0$16.20M$26.46M-$35.92M
Financing cash flow$9.76M$17.82M$15.79M—$55.66M
Depreciation & amortization$1,000$63,000$119,000$169,000$121,000
Stock-based compensation$2.22M$1.12M$1.19M$2.08M$2.26M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.